U.S. Markets closed

ALX Oncology Holdings Inc. (ALXO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
58.22+1.86 (+3.30%)
At close: 4:00PM EDT
58.23 +0.01 (0.02%)
After hours: 04:25PM EDT

ALX Oncology Holdings Inc.

866 Malcolm Road
Suite 100
Burlingame, CA 94010
United States
650 466 7125
http://www.alxoncology.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees24

Key Executives

NameTitlePayExercisedYear Born
Dr. Corey S. GoodmanIndependent Exec. Chairman38.5kN/A1952
Dr. Jaume Pons Ph.D.Pres, CEO & Director1.28MN/A1966
Mr. Peter S. GarciaChief Financial Officer817.65kN/A1962
Dr. Sophia Randolph M.D., Ph.D.Chief Medical Officer & Director938.5kN/A1968
Dr. Michael Chang Ph.D.VP of OperationsN/AN/AN/A
Ms. Shelly PintoVP of Fin. & Chief Accounting OfficerN/AN/A1976
Dr. Michael Warner J.D., Ph.D.Gen. CounselN/AN/AN/A
Ms. Jeanne Y. JewChief Bus. OfficerN/AN/A1964
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.

Corporate Governance

ALX Oncology Holdings Inc.’s ISS Governance QualityScore as of June 1, 2021 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.